Side-by-side · Research reference
FOXO4-DRIvsMT-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED12/45 cited
BFDA-ApprovedHUMAN-REVIEWED9/51 cited
FOXO4-DRI
Senolytic Peptide · D-Retro-Inverso
SQ · Animal models only
MT-1
α-MSH Analogue · FDA-Approved
SQ Implant · 60-Day Release
01Mechanism of Action
Parameter
FOXO4-DRI
MT-1
Primary target
FOXO4-p53 protein complex in senescent cellsBourgeois 2025Tripathi 2021
Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010
Pathway
FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells
α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis
Downstream effect
Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021Alameen 2026
Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010
Feedback intact?
—
Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production
Origin
D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance
Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026
Antibody development
—
—
02Dosage Protocols
Parameter
FOXO4-DRI
MT-1
Animal dose (mouse)
5 mg/kg
SQ injection, aged mouse model (testosterone restoration).
—
Frequency (animal)
Variable — single or intermittent dosing
Protocol-dependent; no standardised regimen.
—
Human equivalent (theoretical)
~0.4 mg/kg (28 mg / 70 kg adult)
Extrapolated using allometric scaling; no clinical validation.
—
Evidence basis
Animal / mechanistic
Phase 3 RCT / FDA-approved orphan drug
Route
SQ (animal)
No human route established.
Subcutaneous implant — upper arm or abdomen
Duration
Weeks to months (animal studies)
Senescent cell clearance observed within weeks.
Seasonal use (spring–autumn typical)
Aligned with peak UV exposure months.
Clinical status
No human trials completed
—
Standard dose
—
16 mg subcutaneous implant
FDA-approved formulation (Scenesse).
Frequency
—
Every 60 days
Sustained release implant — no daily administration required.
Indication
—
Erythropoietic protoporphyria (EPP)
Narrow FDA approval — not licensed for cosmetic tanning.
Stability
—
Norleucine/D-Phe substitutions enhance peptidase resistance
Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).
04Side Effects & Safety
Parameter
FOXO4-DRI
MT-1
Pulmonary hypertension risk
Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023
—
Context-dependent toxicity
Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023
—
Off-target apoptosis
Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)
—
Immune perturbation
Senescent cells contribute to immune surveillance; clearance effects unknown
—
Human safety unknown
No clinical trials — toxicity profile in humans not established
—
Nausea
—
Common (>10%) — mild, transient
Implant site reaction
—
Erythema, bruising, tenderness at insertion site
Hyperpigmentation
—
Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010Habbema 2017
Expected melanogenic response — complicates pigmented lesion surveillance.
Melanocytic changes
—
Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017
Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.
Headache
—
Occasional (MC1R-independent melanocortin effects)
Photosensitivity (paradoxical)
—
Rare phototoxic reactions despite melanin increase
Contamination risk (unregulated)
—
Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010Habbema 2017
Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.
Absolute Contraindications
FOXO4-DRI
- ·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
- ·Pregnancy / lactation (no safety data)
MT-1
- ·Hypersensitivity to afamelanotide or excipients
- ·Hepatic impairment (no safety data)
- ·Renal impairment (no safety data)
Relative Contraindications
FOXO4-DRI
- ·Active malignancy (senescence as tumour suppressor mechanism)
- ·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)
MT-1
- ·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
- ·Pregnancy/lactation (insufficient data)
- ·Photosensitive dermatoses (other than EPP)
05Administration Protocol
Parameter
FOXO4-DRI
MT-1
1. Pre-clinical route
Subcutaneous injection used in rodent models. No human administration protocol exists.
Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.
2. Reconstitution (animal)
Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.
Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.
3. Dosing schedule
Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.
Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.
4. Clinical development status
No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.
New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.
5. Safety monitoring (proposed)
Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.
Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.